{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:35:57Z","timestamp":1770978957778,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer (PCa) is the most frequently diagnosed cancer and the third highest cause of cancer-related deaths in men in the U.S. The development of chemotherapeutic agents that can bind PCa tumor cells with high specificity is critical in order to increase treatment effectiveness. Integrin receptors and their corresponding ligands have different expression patterns in PCa cells. They have been identified as promising targets to inhibit pathways involved in PCa progression. Currently, several compounds have proven to target specific integrins and their subunits in PCa cells. In this article, we review the role of integrins inhibitors in PCa and their potential as therapeutic targets for PCa treatments. We have discussed the following: natural compounds, monoclonal antibodies, statins, campothecins analog, aptamers, d-aminoacid, and snake venom. Recent studies have shown that their mechanisms of action result in decrease cell migration, cell invasion, cell proliferation, and metastasis of PCa cells.<\/jats:p>","DOI":"10.3390\/cancers10020044","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T14:31:17Z","timestamp":1517927477000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Integrin Inhibitors in Prostate Cancer"],"prefix":"10.3390","volume":"10","author":[{"given":"Maylein","family":"Juan-Rivera","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA"},{"name":"University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magaly","family":"Mart\u00ednez-Ferrer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA"},{"name":"University of Puerto Rico Comprehensive Cancer Center, Medical Sciences Campus, San Juan, PR 00936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/ERC-08-0019","article-title":"Integrins in Prostate Cancer Progression","volume":"15","author":"Goel","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ryu, S., Park, K.M., and Lee, S.H. (2016). Gleditsia Sinensis Thorn Attenuates the Collagen-Based Migration of PC3 Prostate Cancer Cells through the Suppression of\u202fIntegrin Expression. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030328"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrm3769","article-title":"The Integrin Adhesome: From Genes and Proteins to Human Disease","volume":"15","author":"Geiger","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/ncb3257","article-title":"Definition of a Consensus Integrin Adhesome and Its Dynamics during Adhesion Complex Assembly and Disassembly","volume":"17","author":"Horton","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_5","unstructured":"(2017, August 30). Cancer Stat Facts: Prostate Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yu, T., Wang, C., Yang, J., Guo, Y., Wu, Y., and Li, X. (2017). Metformin Inhibits SUV39H1-Mediated Migration of Prostate Cancer Cells. Oncogenesis, 9.","DOI":"10.1038\/oncsis.2017.28"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1242\/dev.125.2.327","article-title":"Vinculin Knockout Results in Heart and Brain Defects during Embryonic Development","volume":"125","author":"Xu","year":"1998","journal-title":"Development"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1091\/mbc.7.8.1209","article-title":"Inhibition of Focal Adhesion Kinase (FAK) Signaling in Focal Adhesions Decreases Cell Motility and Proliferation","volume":"7","author":"Gilmore","year":"1996","journal-title":"Mol. Biol. Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.3390\/ijms14059790","article-title":"D-Pinitol Inhibits Prostate Cancer Metastasis through Inhibition of\u202f\u03b1V\u03b23 Integrin by Modulating FAK, c-Src and NF-\u03baB Pathways","volume":"14","author":"Lin","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1104\/pp.66.3.471","article-title":"Carbohydrates in Soybean Nodules: II. Distribution of compounds in seedlings during the onset of nitrogen fixation","volume":"66","author":"Streeter","year":"1980","journal-title":"Plant Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1248\/cpb.38.2862","article-title":"Plant Constituents Biologically Active to Insects. VI. Antifeedants for Larvae of the Yellow Butterfly, Eurema Hecabe Mandarina, in Osmunda Japonica. (2)","volume":"38","author":"Numata","year":"1990","journal-title":"Chem. Pharm. Bull."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0367-326X(00)00267-7","article-title":"Anti-Inflammatory Effect of (+)-Pinitol","volume":"72","author":"Singh","year":"2001","journal-title":"Fitoterapia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1541-7786.MCR-16-0447","article-title":"Abituzumab Targeting of AlphaV-Class Integrins Inhibits Prostate Cancer Progression","volume":"15","author":"Jiang","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-12-0551","article-title":"Targeting Constitutively Activated \u03b21 Integrin Inhibits Prostate Cancer Metastasis","volume":"11","author":"Lee","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/mt.2014.190","article-title":"A Theranostic \u201cSMART\u201d Aptamer for Targeted Therapy of Prostate Cancer","volume":"22","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jcp.24381","article-title":"Suppression of Interactions between Prostate Tumor Cell-Surface Integrin and Endothelial ICAM-1 by Simvastatin Inhibits Micrometastasis","volume":"228","author":"Goc","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1158\/1055-9965.EPI-07-0531","article-title":"Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells","volume":"17","author":"Hoque","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejca.2011.01.005","article-title":"Statins and Prostate Cancer: Molecular and Clinical Aspects","volume":"47","author":"Papadopoulos","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.110.174870","article-title":"Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression","volume":"336","author":"Kochuparambil","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin Use and Reduced Cancer-Related Mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijpharm.2014.02.022","article-title":"A Novel Multifunctional Poly(amidoamine) Dendrimeric Delivery System with Superior Encapsulation Capacity for Targeted Delivery of the Chemotherapy Drug 10-Hydroxycamptothecin","volume":"465","author":"Kong","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1038\/mtna.2016.10","article-title":"Selection and Characterization of an \u03b16\u03b24 Integrin Blocking DNA Aptamer","volume":"5","author":"Berg","year":"2016","journal-title":"Mol. Ther. Acids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/jcb.25673","article-title":"Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells","volume":"118","author":"Das","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/biores.2012.0253","article-title":"Cell-SELEX Technology","volume":"1","author":"Ohuchi","year":"2012","journal-title":"Biores. Open Access"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/mtna.2013.70","article-title":"Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation","volume":"3","author":"Kruspe","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cmdc.201402163","article-title":"Aptamers as Drug Delivery Vehicles","volume":"9","author":"Kruspe","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1038\/mtna.2014.21","article-title":"Cell-Type-Specific, Aptamer-Functionalized Agents for Targeted Disease Therapy","volume":"3","author":"Zhou","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/mt.2014.117","article-title":"Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-Specific Membrane Antigen","volume":"22","author":"Dassie","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10585-013-9634-1","article-title":"A d-Amino Acid Containing Peptide as a Potent, Noncovalent Inhibitor of\u202f\u03b15\u03b21 Integrin in Human Prostate Cancer Invasion and Lung Colonization","volume":"31","author":"Veine","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2174\/138920111796117300","article-title":"Anti-Angiogenic Peptides for Cancer Therapeutics","volume":"12","author":"Rosca","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1158\/0008-5472.CAN-05-4400","article-title":"Role of Focal Adhesion Kinase and Phosphatidylinositol 3 Kinase in Integrin Fibronectin Receptor-Mediated, Matrix Metalloproteinase-1-Dependent Invasion by Metastatic Prostate Cancer Cells","volume":"66","author":"Zeng","year":"2006","journal-title":"Cancer Res."},{"key":"ref_33","first-page":"309","article-title":"Anti-Invasive, Antitumorigenic, and Antimetastatic Activities of the PHSCN Sequence in Prostate Carcinoma","volume":"60","author":"Livant","year":"2000","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1593\/tlo.08187","article-title":"alpha(5)beta(1) Integrin Ligand PHSRN Induces Invasion and alpha(5) mRNA in Endothelial Cells to Stimulate Angiogenesis","volume":"2","author":"Zeng","year":"2009","journal-title":"Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sayeed, A., Fedele, C., Trerotola, M., Ganguly, K.K., and Languino, L.R. (2013). IGF-IR Promotes Prostate Cancer Growth by Stabilizing\u202f\u03b15\u03b21 Integrin Protein Levels. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076513"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pros.21173","article-title":"The Disintegrin Contortrostatin in Combination with Docetaxel Is a Potent Inhibitor of Prostate Cancer in Vitro and in Vivo","volume":"70","author":"Lin","year":"2010","journal-title":"Prostate"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000092418","article-title":"Contortrostatin, a Snake Venom Disintegrin with Anti-Angiogenic and Anti-Tumor Activity","volume":"34","author":"Swenson","year":"2006","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_38","first-page":"4993","article-title":"Contortrostatin, a Snake Venom Disintegrin, Inhibits\u202f\u03b21 Integrin-Mediated Human Metastatic Melanoma Cell Adhesion and Blocks Experimental Metastasis","volume":"54","author":"Trikha","year":"1994","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.499.3.4","article-title":"Intravenous Liposomal Delivery of the Snake Venom Disintegrin Contortrostatin Limits Breast Cancer Progression","volume":"3","author":"Swenson","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025461507027","article-title":"Inhibition of alpha(v)beta3 Integrin Reduces Angiogenesis, Bone Turnover, and Tumor Cell Proliferation in Experimental Prostate Cancer Bone Metastases","volume":"20","author":"Nemeth","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3851\/IMP2291","article-title":"Contortrostatin, a Homodimeric Disintegrin Isolated from Snake Venom Inhibits Herpes Simplex Virus Entry and Cell Fusion","volume":"17","author":"Hubbard","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1593\/neo.11122","article-title":"Targeting of \u03b1 v-Integrins in Stem\/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in","volume":"13","author":"Cancer","year":"2011","journal-title":"Neoplasia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-04-1223","article-title":"Inhibition of \u03b1v\u03b23 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy","volume":"11","author":"Abdollahi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/0008-5472.CAN-05-3071","article-title":"\u03b21 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In Vivo","volume":"66","author":"Park","year":"2010","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","article-title":"Antibody-Mediated Blockade of Integrin A v B 6 Inhibits Tumor Progression In Vivo by a Transforming Growth Factor-B\u2013Regulated Mechanism","volume":"68","author":"Leone","year":"2008","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ymthe.2005.05.012","article-title":"Targeting ECM\u2014Integrin Interaction with Liposome-Encapsulated Small Interfering RNAs Inhibits the Growth of Human Prostate Cancer in a Bone Xenograft Imaging Model","volume":"12","author":"Bisanz","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1743-7563.2009.01266.x","article-title":"Evaluation of the Safety, Pharmacokinetics and Treatment Effects of an alpha(nu)beta(3) Integrin Inhibitor on Bone Turnover and Disease Activity in Men with Hormone-Refractory Prostate Cancer and Bone Metastases","volume":"6","author":"Rosenthal","year":"2010","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10637-010-9573-5","article-title":"Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD\/PCF prostate cancer clinical trials consortium","volume":"30","author":"Alva","year":"2012","journal-title":"Invest. New Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1007\/s10637-010-9420-8","article-title":"Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium","volume":"29","author":"Bradley","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3816\/CGC.2006.n.012","article-title":"Current Trial Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer\u202f: Scientific Rationale and Study Design","volume":"4","author":"Beekman","year":"2006","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/2\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:53:52Z","timestamp":1760194432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/2\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"alternative-id":["cancers10020044"],"URL":"https:\/\/doi.org\/10.3390\/cancers10020044","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]}}}